Taysha Gene Therapies (Nasdaq: TSHA) granted equity awards to four new employees on June 1, 2026 under its 2023 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards include 714,700 RSUs and options for 468,600 shares at a $5.97 exercise price, vesting over four years, subject to continued service.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – TSHA
-6.62%
-6.62%Session close to close
In the Jun 5 session, TSHA declined 6.62%, reflecting a notable negative market reaction.
The stock moved -6.6% in the session following this news. A negative reaction despite this routine i...
Analysis
The stock moved -6.6% in the session following this news. A negative reaction despite this routine inducement grant would fit a pattern where not all positive or neutral updates support the share price, as seen after some preclinical and scheduling announcements. The grants cover 714,700 RSUs and options on 468,600 shares at $5.97, structured over a four‑year vesting period. Even within a broader uptrend versus the $2.25 52‑week low, elevated short interest at 15.59% could amplify downside moves following news.
Key Figures
RSU grant size:714,700 sharesStock option grant:468,600 sharesOption exercise price:$5.97+3 more
6 metrics
RSU grant size714,700 sharesAggregate RSUs to four new employees under 2023 Inducement Plan
Stock option grant468,600 sharesAggregate options to four new employees under 2023 Inducement Plan
Option exercise price$5.97Equal to TSHA closing price on June 1, 2026 grant date
Option term10 yearsContractual life of inducement stock options
Initial option vesting25%Vests on first anniversary of vesting commencement date
Reported FY 2025 results and Rett program milestones with strong cash position.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news, especially earnings and program updates, has more often seen share-price moves align with the generally positive tone than diverge.
Recent Company History
Over the last six months, Taysha has focused on advancing TSHA‑102 and strengthening its financial position. Earnings updates on Mar 19, 2026 and May 6, 2026 highlighted REVEAL and ASPIRE trial progress, FDA alignment on the BLA pathway, and cash runway into 2028, with modest positive price reactions. Other items included inducement equity grants on May 1, 2026 and preclinical Rett data on Apr 27, 2026. Today’s additional inducement grants fit a continuing pattern of equity-based hiring and compensation activity.
"granted four new employees, in the aggregate, restricted stock units (RSUs)"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"The RSUs and stock option were granted under the Taysha Gene Therapies, Inc."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4)regulatory
"as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionfinancial
"and an option to purchase 468,600 shares of the Company's common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise pricefinancial
"The stock option has an exercise price of $5.97 which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement datefinancial
"beginning on the first anniversary of the award's vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date. The stock option has an exercise price of $5.97 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.
About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact: Hayleigh Collins Senior Director, Corporate Communications and Investor Relations Taysha Gene Therapies, Inc. hcollins@tayshagtx.com
What equity inducement grant did Taysha Gene Therapies (TSHA) announce on June 5, 2026?
Taysha Gene Therapies announced equity awards to four new employees, including RSUs and stock options. According to Taysha, the grants cover 714,700 restricted stock units and options for 468,600 shares of common stock as employment inducements.
How many RSUs were granted in Taysha Gene Therapies' June 2026 inducement award for TSHA employees?
Taysha Gene Therapies granted an aggregate of 714,700 RSUs to four new employees. According to Taysha, these restricted stock units vest in four equal annual installments, starting on the first anniversary of the vesting commencement date, contingent on continued service.
What are the key terms of the TSHA stock options in Taysha Gene Therapies' June 2026 inducement grant?
The stock options cover 468,600 TSHA shares with a $5.97 exercise price. According to Taysha, they have a 10-year term and vest 25% after one year, with the remaining 75% vesting in equal monthly installments over the following 36 months.
How does the vesting schedule work for Taysha Gene Therapies' June 2026 RSU inducement grants for TSHA?
The RSUs vest in four equal annual installments over four years. According to Taysha, vesting begins on the first anniversary of the vesting commencement date and requires each employee’s continued service with the company on every vesting date.
Under which plan and Nasdaq rule were Taysha Gene Therapies' June 2026 TSHA inducement grants issued?
The inducement awards were granted under the 2023 Inducement Plan. According to Taysha, these RSUs and options qualify as employment inducement grants made in accordance with Nasdaq Listing Rule 5635(c)(4) for newly hired employees.
Do the June 2026 TSHA stock option inducement grants from Taysha Gene Therapies depend on continued service?
Yes, vesting of the stock options depends on ongoing employment. According to Taysha, both the initial 25% tranche and the remaining 75% monthly vesting over 36 months require each employee to remain in service on the respective vesting dates.
